A recent study suggests that people who discontinue new GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end traditional lifestyle plans.
Research printed in a major medical journal demonstrates that while obese people frequently drop substantial amounts of their body weight while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Individuals buying such drugs need to be informed of the danger of rapid rebound weight gain when the medication ends," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to original weight within about 18 months.
Weighing Therapies
The analysis, which looked at dozens of trials involving over 9,000 of participants, compared the effects of these new drugs with conventional dieting.
The team point out that people who lose weight through dieting typically experience a slower creep back—approximately 0.1 kg a month—post-intervention.
Explaining the Quick Regain
Nutrition scientists propose the way of the drugs is key to understanding the heightened regain.
These medications copy a natural hormone called glucagon-like peptide-1, which controls hunger.
"Artificially providing GLP-1 levels several times higher than the body's typical production could lead to the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this hormone supplement results in appetite is uncontrolled, making binge eating far more likely."
A Chronic Condition?
Medical guidelines advise the jabs for people with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Professionals say that, due to the significant potential of relapse, the treatment might need to be ongoing.
This opinion is supported by pharmaceutical companies, who state that the findings "emphasize the chronic nature of obesity," akin to managing conditions like high blood pressure.
User Testimonies
People who have discontinued the medication report a intense return of cravings.
"I experienced a switch that goes on and I was suddenly extremely hungry," described an individual.
This challenge is compounded if individuals have not established permanent dietary or behavioural modifications during treatment.
Significant Adoption
Recent estimates suggest that millions of adults in the UK have used these injections in the last 12 months, with interest continuing to grow.
- Use is greater among females than males.
- The middle-aged age group shows the greatest usage rates.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, experts caution that while GLP-1 drugs are effective agents for weight loss, they are not a magic cure and long-term success hinges on combined lifestyle management.
